[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-342246-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-342246-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","improving-pd-1-blockade-plus-chemotherapy-for-complete-remission-of-lung-cancer-by-nanopdlim2","Improving PD-1 blockade plus chemotherapy for complete remission of lung cancer by nanoPDLIM2","","Immune checkpoint inhibitors and their combinations with therapies such as chemotherapy fail for most cancer patients. Previously, PDLIM2 was identified as a tumor suppressor repressed in lung cancer, driving resistance to cancer treatment. This study uses human samples and a clinically feasible nano-delivery system to test nanoPDLIM2 plasmids with PD-1 antibody and chemotherapy, showing genetic and epigenetic PDLIM2 repression, low toxicity, high tumor specificity, and strong antitumor efficacy with frequent complete remission.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/improving-pd-1-blockade-plus-chemotherapy-for-complete-remission-of-lung-cancer-by-nanopdlim2/342246/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/improving-pd-1-blockade-plus-chemotherapy-for-complete-remission-of-lung-cancer-by-nanopdlim2/342246.png","ImageObject",300,407,{"name":42,"@type":43},"Theodora","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-04","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why do immune checkpoint inhibitors and chemotherapy underperform in most lung cancer patients?","Question",{"text":63,"@type":64},"Most patients do not respond effectively to immune checkpoint inhibitors (ICIs) and their combinations with therapies such as chemotherapy. The study links this limited efficacy to resistance mechanisms driven by low PDLIM2 activity in tumors.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What is nanoPDLIM2, and what combination therapy is tested?",{"text":68,"@type":64},"nanoPDLIM2 is a nanoparticle-encapsulated PDLIM2 expression plasmid delivered systemically. The study evaluates its therapeutic efficacy together with PD-1 antibody and chemotherapeutic drugs.",{"name":70,"@type":61,"acceptedAnswer":71},"What mechanisms does nanoPDLIM2 use to enhance anti-PD-1 and chemotherapy efficacy?",{"text":72,"@type":64},"nanoPDLIM2 increases MHC-I expression, suppresses MDR1 induction and survival-related tumor gene expression, and enhances lymphocyte infiltration. This converts “cold” tumors into “hot” tumors that become more sensitive to ICIs and chemotherapeutic drugs.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},342246,1792142282,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},687197207919,"https://ap-avatar.wpscdn.com/avatar/a000253d6f5f7c60be?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779446848396160552","ReSeARCH ARtICLe  \n*For correspondence:  \n[Gutian.Xiao@med.usc.edu](Gutian.Xiao@med.usc.edu) (GX); [Zhaoxia.Qu@med.usc.edu](Zhaoxia.Qu@med.usc.edu) (ZQ)  \nCompeting interest: The authors declare that no competing interests exist.  \nFunding: See page 15  \nSent for Review  \n25 June 2023  \nPreprint posted  \n25 July 2023  \nReviewed preprint posted  \n24 August 2023  \nReviewed preprint revised  \n13 February 2024  \nVersion of Record published  \n24 December 2024  \nReviewing Editor: Carla VRothlin, Yale University, United States  \n Copyright Sun et al. This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use andredistribution provided that the original author and source are credited.  \nImproving PD-1 blockade plus chemotherapy for complete remission of lung cancer by nanoPDLIM2  \nFan Sun1, Pengrong Yan1, Yadong Xiao1,2,3,4, Hongqiao Zhang3, Steven D Shapiro2,4, Gutian Xiao1,3*, Zhaoxia Qu1,3*  \n1 UPMC Hillman Cancer Center, Department of Microbiology and Molecular Genetics, University of Pittsburgh School of Medicine, Pittsburgh, United States; 2 Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, United States; 3 Norris Comprehensive Cancer Center, Hastings Center for Pulmonary Research, Department of Molecular Microbiology and Immunology, University of Southern California Keck School of Medicine, Los Angeles, United States; 4 Department of Medicine, University of Southern California Keck School of Medicine, Los Angeles, United States  \n\n| eLife assessment\u003Cbr>This study presents a valuable finding for the immunotherapy of cancer. The data support the role of PDLIM2 as a tumor suppressor, and more immediately, its relevance for strategies to improve the efficacy of immunotherapy. The evidence supporting the conclusions is compelling and the work will be of interest to biomedical scientists working on cancer immunology. |\n| --- |\n| Abstract Immune checkpoint inhibitors (ICIs) and their combination with other therapies such as chemotherapy, fail in most cancer patients. We previously identified the PDZ-LIM domaincontaining protein 2 (PDLIM2) as a bona fide tumor suppressor that is repressed in lung cancer to drive cancer and its chemo and immunotherapy resistance, suggesting a new target for lung cancer therapy improvement. In this study, human clinical samples and data were used to investigate PDLIM2 genetic and epigenetic changes in lung cancer. Using an endogenous mouse lung cancer model faithfully recapitulating refractory human lung cancer and a clinically feasible nano-delivery system, we investigated the therapeutic efficacy, action mechanism, and safety of systemically administrated PDLIM2 expression plasmids encapsulated in nanoparticles (nanoPDLIM2) and its combination with PD-1 antibody and chemotherapeutic drugs. Our analysis indicate that PDLIM2 repression in human lung cancer involves both genetic deletion and epigenetic alteration. NanoPDLIM2 showed low toxicity, high tumor specificity, antitumor activity, and greatly improved the efficacy of anti-PD-1 and chemotherapeutic drugs, with complete tumor remission in most mice and substantial tumor reduction in the remaining mice by their triple combination. Mechanistically, nanoPDLIM2 increased major histocompatibility complex class I (MHC-I) expression, suppressed multi-drug resistance 1 (MDR1) induction and survival genes and other tumor-related genes expression in tumor cells, and enhanced lymphocyte tumor infiltration, turning the cold tumors hot and sensitive to ICIs and rendering them vulnerable to chemotherapeutic drugs and activated tumorinfiltrating lymphocytes (TILs) including those unleashed by ICIs. These studies established a clinically applicable PDLIM2-based combination therapy with great efficacy for lung cancer and possibly other cold cancers. |\n\nSun et al. eLife 2023;12:RP89638. DOI: [https://doi.org/10.7554/e","cbCaiderTqLb1pr1","https://ap.wps.com/l/cbCaiderTqLb1pr1","pdf",7857758,18,"English","# eLife assessment\n## Abstract\n# eLife digest\n## Introduction","[{\"question\":\"Why do immune checkpoint inhibitors and chemotherapy underperform in most lung cancer patients?\",\"answer\":\"Most patients do not respond effectively to immune checkpoint inhibitors (ICIs) and their combinations with therapies such as chemotherapy. The study links this limited efficacy to resistance mechanisms driven by low PDLIM2 activity in tumors.\"},{\"question\":\"What is nanoPDLIM2, and what combination therapy is tested?\",\"answer\":\"nanoPDLIM2 is a nanoparticle-encapsulated PDLIM2 expression plasmid delivered systemically. The study evaluates its therapeutic efficacy together with PD-1 antibody and chemotherapeutic drugs.\"},{\"question\":\"What mechanisms does nanoPDLIM2 use to enhance anti-PD-1 and chemotherapy efficacy?\",\"answer\":\"nanoPDLIM2 increases MHC-I expression, suppresses MDR1 induction and survival-related tumor gene expression, and enhances lymphocyte infiltration. This converts “cold” tumors into “hot” tumors that become more sensitive to ICIs and chemotherapeutic drugs.\"}]","Improving PD-1 blockade plus chemotherapy for complete remission of lung cancer by nanoPDLIM2 | PDF",1790045905,45,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c8f5a78aa166ca6bf7493381e04f987e.webp",983,1272,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4a48e4960576be61c49439a15779e7b2.webp",982,1270,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/23b9f1a7673a875bc871eaa887b954ef.webp",981,1269,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1cae06b84d330b531cd45f079718328a.webp",980,1268]